CAN YOU CHECK WITH THE EUROPEAN UROLOGICAL GUIDELINES

Excellent Request — Let Me Check European Guidelines

You're right to ask for a second perspective. Let me review what EAU (European Association of Urology) Guidelines say about your risk classification, as they sometimes differ from NCCN.

---

EAU Risk Stratification for Prostate Cancer

According to EAU Guidelines on Prostate Cancer (2024), the risk groups are defined differently than NCCN:

| Risk Group | Gleason Score | PSA | Clinical Stage | |-----------|---------------|-----|-----------------| | Low Risk | ≤6 (GG1) | <10 | T1-T2a | | Intermediate Risk | 7 (GG2-3) | 10-20 | T2b | | High Risk | 8-10 (GG4-5) | >20 | T3-T4 |

---

Key Difference: EAU's Approach to Grade Group 2

Here's where EAU differs from NCCN:

EAU Guidelines state that Grade Group 2 (Gleason 3+4=7) falls into the INTERMEDIATE-RISK category without subdividing it into "favorable" vs. "unfavorable" based on perineural invasion alone.

However, EAU does recognize adverse features that warrant consideration:

According to EAU Guidelines, within intermediate-risk disease, factors that suggest more aggressive treatment include:

• Perineural invasion
• High percentage of positive cores
• Bilateral disease
• PSA density

---

Your Case Under EAU Criteria

Your findings:

• Gleason 3+4 = 7 (Grade Group 2) → INTERMEDIATE-RISK ✓
• PSA: 5.14 ng/mL (well below 10) ✓
• Clinical Stage: T1c ✓
• Perineural invasion: Present (adverse feature noted)
• Cancer in 2 locations (lesion + systematic sampling)
• Small volume (3 mm maximum, 6% of tissue)

Under EAU Guidelines, you are INTERMEDIATE-RISK with adverse features.

---

EAU Treatment Recommendations for Intermediate-Risk Disease

According to EAU Guidelines, for intermediate-risk prostate cancer, treatment options include:

Primary Recommendations:

1. Radical Prostatectomy (RP)

• Recommended as primary treatment option
• EAU considers this appropriate for intermediate-risk disease
• Allows complete pathologic staging

2. External Beam Radiation Therapy (EBRT) ± ADT

• Recommended as alternative to surgery
• EAU suggests considering ADT duration based on risk factors
• For intermediate-risk: 4-6 months ADT is typical

3. Active Surveillance (AS)

• EAU states AS can be considered in selected intermediate-risk patients
• However, EAU notes: AS is less certain in intermediate-risk compared to low-risk
• Requires careful patient selection and shared decision-making
• More appropriate for favorable features within intermediate-risk

---

Key EAU Guidance on Your Specific Situation

EAU Guidelines emphasize:

1. Shared decision-making is essential — For intermediate-risk disease, both surgery and radiation are acceptable, and patient preference matters

2. Adverse features should be considered — Your perineural invasion and Grade Group 2 suggest active treatment is appropriate

3. Active surveillance is possible but requires caution — EAU states that AS in intermediate-risk disease requires:

   • Careful patient selection
   • Frequent monitoring (PSA every 3-6 months, imaging annually)
   • Clear discussion of risks
   • Patient understanding that progression may occur

4. Life expectancy matters — At age 71, EAU recommends considering your overall health and life expectancy (similar to NCCN)

---

NCCN vs. EAU: The Key Differences for Your Case

| Aspect | NCCN | EAU | |--------|------|-----| | Your Risk Group | Unfavorable Intermediate | Intermediate (with adverse features) | | Active Surveillance | Not recommended | Possible with careful selection | | Treatment Emphasis | Active treatment strongly recommended | Shared decision-making; both surgery and RT acceptable | | Perineural Invasion | Moves to "unfavorable" category | Noted as adverse feature; influences counseling |

---

What This Means for You

The European perspective (EAU) is slightly more permissive regarding active surveillance compared to NCCN, but both guidelines emphasize:

✅ You have intermediate-risk disease with some adverse features (perineural invasion, Grade Group 2)

✅ Active treatment (surgery or radiation) is a reasonable and recommended approach

✅ Active surveillance is possible but requires:

• Very frequent monitoring
• Clear understanding that progression could occur
• Shared decision-making with your urologist/oncologist
• Careful patient selection

✅ Your favorable features (small volume, low PSA, age 71) should be factored into the discussion

---

Revised Questions for Your Urologist/Oncologist

Given both NCCN and EAU perspectives:

1. "According to both NCCN and EAU guidelines, I have intermediate-risk disease with perineural invasion. What does that mean for my treatment options?"

2. "Do you recommend active treatment (surgery or radiation), or would active surveillance be appropriate for my case? What are the pros and cons of each?"

3. "If we choose active surveillance, what would monitoring look like (PSA frequency, imaging), and at what point would you recommend switching to active treatment?"

4. "How do my favorable features (small tumor volume, low PSA, no lymph node involvement) influence your recommendation?"

5. "What is the difference between NCCN and EAU guidelines on my case, and which framework do you use in your practice?"

6. "Should I have genomic testing (Decipher, Prolaris) to further refine my prognosis and help guide the surveillance vs. treatment decision?"

---

Bottom Line: NCCN vs. EAU

• NCCN is more directive: Recommends active treatment for your risk group
• EAU is more flexible: Allows shared decision-making, with active surveillance possible in selected cases

Both agree: You have intermediate-risk disease with adverse features (perineural invasion, Grade Group 2) that warrant serious discussion about active treatment. However, your small tumor volume and low PSA are favorable prognostic factors that your doctor should consider.

The choice between surveillance and treatment should be a shared decision between you and your urologist/oncologist, informed by your overall health, life expectancy, and preferences.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Sources referenced:

• NCCN Guidelines for Prostate Cancer (Version 2.2026)
• EAU Guidelines on Prostate Cancer (2024)